Status:
UNKNOWN
Trial Comparing Two Carboplatin Doses in Groups C and D Intraocular Retinoblastoma
Lead Sponsor:
All India Institute of Medical Sciences
Collaborating Sponsors:
Council of Scientific and Industrial Research, India
Conditions:
Intraocular Retinoblastoma
Eligibility:
All Genders
Phase:
NA
Brief Summary
The purpose of this study is to determine whether an increase in the dose of carboplatin in treatment of advanced intraocular (group C and D) retinoblastoma helps in avoiding radiotherapy and improves...
Detailed Description
Chemoreduction has become an important method in management of retinoblastoma. This technique has been employed in an effort to avoid enucleation and external beam radiotherapy (EBRT) for children wit...
Eligibility Criteria
Inclusion
- All new cases of retinoblastoma with group C or D tumor as per the ICRB (International classification of retinoblastoma, Table 2) that present at Rajendra Prasad Centre for Ophthalmic Sciences over first 2 years of the study period
Exclusion
- Biomicroscopic evidence of iris neovascularization
- Neovascular glaucoma
- Tumor invasion into the anterior chamber, iris, optic nerve, choroid, or extraocular tissues as documented by clinical, ultrasonographic, and neuroimaging modalities.
- Systemic exclusion criteria include:
- evidence of systemic metastasis
- prior chemotherapy
- prior treatment for retinoblastoma, or
- inadequate renal or hepatic function
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2012
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00889018
Start Date
April 1 2009
End Date
April 1 2012
Last Update
February 9 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dr RPC AIIMS
Delhi, National Capital Territory of Delhi, India, 110029